Investcorp, a Bahrain-based asset management company has made its second successive investment in the Chinese healthcare industry, this time in Kindstar lobalgene (“Kindstar”), a leading medical testing services group.
Wuhan-based independent medical testing provider, Kindstar was founded in 2003. It provides advanced specialty testing services to the patients and physicians in hematology, gynecology and pediatrics, infectious diseases, oncology and neurology.
The Chinese company currently offers its services to more than 3,000 hospitals in over 600 cities of the country with advanced and nationally accredited clinical testing, scientific research and development laboratories.
“Investcorp is proud of the Asian investment platform that it has built over the past five years. Our focus on healthcare opportunities in China allowed us to identify Kindstar which has built impressive capabilities for improving the quality of healthcare through severe diseases related testing. We believe that Kindstar has significant growth potential driven by accelerating demand for precision medicine, an underserved market.”
The independent clinical laboratory market of China is estimated to make fast pace growth in the foreseeable future, as esoteric testing is surpassing the overall market, driven by the increasing demand to address unmet medical needs.
The Kindstar is further supported by a huge global network, including some of the world’s leading healthcare organizations like the US-based Mayo Clinic and Illumina and Switzerland headquartered pharmaceutical company Novartis.
The current funding made by Investcorp is in line with its mission to invest in leading Chinese healthcare companies that stayed strong throughout the pandemic and expected to have significant growth.
In September 2020, Investcorp obtained minority shares in Lu Daopei Medical Group, a leading hematology hospital group in China and WeDoctor, a well-known online healthcare services company.